Skip to main content

Advertisement

SpringerLink
Log in

Crohn’s disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Crohn’s disease is an idiopathic chronic intestinal illness that requires specialized medical care for prompt disease diagnosis and appropriate management. Clinicians must accurately interpret and integrate findings from multitude of sources in order to achieve diagnostic certainty. Ileocolonoscopy remains the most relied modality, allowing for a direct mucosal visualization and biopsies for histologic assessments. Serologic markers currently serve an adjunctive role, often utilized in attempts to further subtype patients with indeterminate colitis. Radiologic imaging, such as computed tomography enterography can evaluate the far reaches of the small intestine, while also providing information about penetrating complications and extraintestinal disease manifestations. Treatment options and strategies continue to evolve with new biologic agents and ongoing testing of aggressive “top–down” approaches. In addition, identification of increased colorectal cancer risks in individuals with Crohn’s colitis has led to formal surveillance guidelines. The clinical diagnosis and management of Crohn’s disease continues to be an area of rapid change and exciting developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517

    Article  PubMed  Google Scholar 

  2. Rothfuss KS, Stange EF, Herrlinger KR (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12:4819–4831

    PubMed  CAS  Google Scholar 

  3. Benson L, Song X, Campos J, Singh N (2007) Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 28(11):1233–1235

    Article  PubMed  Google Scholar 

  4. Koutroubakis IE, Petinaki E, Mouzas IA, et al. (2001) Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 96:449–454

    PubMed  CAS  Google Scholar 

  5. Quinton JF, Sendid B, Reumaux D, et al. (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42:788–791

    Article  PubMed  CAS  Google Scholar 

  6. Sandborn WJ, Loftus EV Jr, Colombel JF, et al. (2001) Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 7:192–201

    Article  PubMed  CAS  Google Scholar 

  7. Peeters M, Joossens S, Vermeire S, et al. (2001) Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96:730–734

    Article  PubMed  CAS  Google Scholar 

  8. Linskens RK, Mallant-Hent RC, Groothuismink ZM, et al. (2002) Evaluation of serological markers to differentiate between ulcerative colitis and Crohn’s disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 14:1013–1018

    Article  PubMed  CAS  Google Scholar 

  9. Austin GL, Shaheen NJ, Sandler RS (2006) Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am J Gastroenterol 101:413–416

    Article  PubMed  Google Scholar 

  10. Dubinsky MC, Lin YC, Dutridge D, et al. (2006) Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol 101:360–367

    Article  PubMed  Google Scholar 

  11. Bruining DH, Siddiki H, Fletcher JG, et al. (2007) Prevalence of penetrating disease and extraintestinal manifestations of Crohn’s disease detected with CT enterography {abstract}. Gastroenterology 132:A-650

    Google Scholar 

  12. Solem C, Loftus EV, Fletcher JG, et al. (2008) Small bowel imaging in Crohn’s disease (CD): a prospective, blinded, 4-way comparison trial. Gastrointest Endosc in press

  13. Bodily KD, Fletcher JG, Solem CA, et al. (2006) Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography—correlation with endoscopic and histologic findings of inflammation. Radiology 238:505–516

    Article  PubMed  Google Scholar 

  14. Booya F, Fletcher JG, Huprich JE, et al. (2006) Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241:787–795

    Article  PubMed  Google Scholar 

  15. Colombel JF, Solem CA, Sandborn WJ, et al. (2006) Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 55:1561–1567

    Article  PubMed  CAS  Google Scholar 

  16. Higgins PD, Caoili E, Zimmermann M, et al. (2006) Computed tomographic enterography adds information to clinical management in small bowel Crohn’s disease. Inflamm Bowel Dis 13:262–268

    Article  Google Scholar 

  17. Brenner DJ, Hall EJ (2007) Computed tomography—an increasing source of radiation exposure. N Engl J Med 357(22): 2277–2284

    Article  PubMed  CAS  Google Scholar 

  18. Martin DR, Semelka RC (2006) Health effects of ionising radiation from diagnostic CT. Lancet 367:1712–1714

    Article  PubMed  Google Scholar 

  19. Peloquin J, Pardi D, Sandborn W, et al. (2006) Exposure to diagnostic ionizing radiation in a population-based cohort of patients with inflammatory bowel disease {abstract}. Am J Gastroenterol 101:S448–S449

    Google Scholar 

  20. Siddiki H, Fletcher J, Bruining D, et al. (2007) Performance of lower-dose CT enterography for detection of inflammatory bowel disease. RSNA abstract Chicago, Illinois SSA 10–2:254

  21. Triester SL, Leighton JA, Leontiadis GI, et al. (2006) A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn’s disease. Am J Gastroenterol 101:954–964

    Article  PubMed  Google Scholar 

  22. Kettritz U, Isaacs K, Warshauer DM, et al. (1995) Crohn’s disease. Pilot study comparing MRI of the abdomen with clinical evaluation. J Clin Gastroenterol 21:249–253

    Article  PubMed  CAS  Google Scholar 

  23. Florie J, Horsthuis K, Hommes DW, et al. (2005) Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn’s disease. Clin Gastroenterol Hepatol 3:1221–1228

    Article  PubMed  Google Scholar 

  24. Bernstein CN, Greenberg H, Boult I, et al. (2005) A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn’s disease. Am J Gastroenterol 100:2493–2502

    Article  PubMed  Google Scholar 

  25. Best WR, Becktel JM, Singleton JW, et al. (1976) Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444

    PubMed  CAS  Google Scholar 

  26. Frenz MB, Dunckley P, Camporota L, et al. (2005) Comparison between prospective and retrospective evaluation of Crohn’s disease activity index. Am J Gastroenterol 100:1117–1120

    Article  PubMed  Google Scholar 

  27. Shillon S, Loftus E (2005) Medical therapy in Crohn’s disease. Curr Treat Options Gastroenterol 8:19–30

    Article  Google Scholar 

  28. Summers RW, Switz DM, Sessions JT Jr, et al. (1979) National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 77:847–869

    PubMed  CAS  Google Scholar 

  29. Hanauer SB, Stromberg U (2004) Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2:379–388

    Article  PubMed  CAS  Google Scholar 

  30. Akobeng AK, Gardener E (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev CD003715

  31. Sutherland L, Singleton J, Sessions J, et al. (1991) Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 32:1071–1075

    Article  PubMed  CAS  Google Scholar 

  32. Brandt LJ, Bernstein LH, Boley SJ, et al. (1982) Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387

    PubMed  CAS  Google Scholar 

  33. Kane SV, Schoenfeld P, Sandborn WJ, et al. (2002) The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 16:1509–1517

    Article  PubMed  CAS  Google Scholar 

  34. Thomsen OO, Cortot A, Jewell D, et al. (1998) A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 339:370–374

    Article  PubMed  CAS  Google Scholar 

  35. Sandborn WJ, Lofberg R, Feagan BG, et al. (2005) Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100:1780–1787

    Article  PubMed  CAS  Google Scholar 

  36. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260

    Article  PubMed  CAS  Google Scholar 

  37. Munkholm P, Langholz E, Davidsen M, et al. (1994) Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 35:360–362

    Article  PubMed  CAS  Google Scholar 

  38. Pearson DC, May GR, Fick G, et al. (1998) Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev CD000067

  39. Sandborn W, Sutherland L, Pearson D, et al. (1998) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev CD000545

  40. Alfadhli AAF, McDonald JWD, Feagan BG (2004) Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev CD003459

  41. Targan SR, Hanauer SB, van Deventer SJ, et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337:1029–1035

    Article  PubMed  CAS  Google Scholar 

  42. Hanauer SB, Feagan BG, Lichtenstein GR, et al. (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 359:1541–1549

    Article  PubMed  CAS  Google Scholar 

  43. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333

    Article  PubMed  CAS  Google Scholar 

  44. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65

    Article  PubMed  CAS  Google Scholar 

  45. Present DH, Rutgeerts P, Targan S, et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  PubMed  CAS  Google Scholar 

  46. Sands BE, Anderson FH, Bernstein CN, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    Article  PubMed  CAS  Google Scholar 

  47. Sandborn WJ, Rutgeerts P, Enns R, et al. (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838

    PubMed  Google Scholar 

  48. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413

    Article  PubMed  CAS  Google Scholar 

  49. Lichtenstein GR, Yan S, Bala M, et al. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 128:862–869

    Article  PubMed  CAS  Google Scholar 

  50. Feagan B, Panaccione R, Sandborn W, et al. (2007) An evaluation of adalimumab on the risk of hospitalization in patients with Crohn’s disease, data from CHARM {abstract}. Gastroenterology 132(4 Suppl 2):A513

    Google Scholar 

  51. Schreiber S, Reinsich R, Colombel JF, et al. (2007) Early Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM {abstract}. Gastroenterology 132:A-147

    Google Scholar 

  52. Schreiber S, Colombel J, Panes J, et al. (2006) Recent onset Crohn’s disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: results from the analysis of the PRECISE III Study {abstract}. Gut 55(suppl II):A131

    Google Scholar 

  53. Hommes D, Baert F, van Assche G, et al. (2006) The ideal management of Crohn’s disease: top down versus step up strategies, a randomized controlled trial {abstract}. Gastroenterology 130:A108–A109

    Google Scholar 

  54. D’Haens G, Hommes D, Baert F, et al. (2006) A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn’s disease (abstract). Gastroenterology 130:A110

    Google Scholar 

  55. Reddy JG, Loftus EV Jr (2006) Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 35:837–855

    Article  PubMed  Google Scholar 

  56. Sandborn WJ, Colombel JF, Enns R, et al. (2005) Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353:1912–1925

    Article  PubMed  CAS  Google Scholar 

  57. Targan SR, Feagan BG, Fedorak RN, et al. (2007) Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 132:1672–1683

    Article  PubMed  CAS  Google Scholar 

  58. Van Assche G, Van Ranst M, Sciot R, et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368

    Article  PubMed  Google Scholar 

  59. Munkholm P, Langholz E, Davidsen M, et al. (1993) Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 105:1716–1723

    PubMed  CAS  Google Scholar 

  60. Dhillon S, Loftus EJ, Tremaine W, et al. (2005) The natural history of surgery for Crohn’s disease in a population-based cohort from Olmsted County, Minnesota {abstract}. Gastroenterology 100(9 suppl):S305

    Google Scholar 

  61. Ekbom A, Helmick C, Zack M, et al. (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 336:357–359

    Article  PubMed  CAS  Google Scholar 

  62. Rubin DT, Kavitt RT (2006) Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am 35:581–604

    Article  PubMed  Google Scholar 

  63. Itzkowitz SH, Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634–1648

    Article  PubMed  Google Scholar 

  64. Itzkowitz SH, Present DH, Crohn’s, Colitis Foundation of America Colon Cancer in IBDSG (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314–321

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr. Loftus has received research support from Techlab, Inc, Given Imaging, Schering-Plough, Abbott Labs, UCB Pharma, PDL Biopharma, and Procter & Gamble. Dr. Loftus has served as a consultant for Prometheus Laboratories, UCB Pharma, Abbott Labs, PDL Biopharma, Elan, Bristol Myers Squibb, Procter & Gamble, Shire, and Salix.

Author information

Authors and Affiliations

  1. Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA

    David H. Bruining & Edward V. Loftus Jr

  2. Division of Gastroenterology & Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA

    Edward V. Loftus Jr

Authors
  1. David H. Bruining
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward V. Loftus Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward V. Loftus Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruining, D.H., Loftus, E.V. Crohn’s disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know. Abdom Imaging 34, 297–302 (2009). https://doi.org/10.1007/s00261-008-9410-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-008-9410-x

Keywords

Search

Navigation